310 related articles for article (PubMed ID: 23129123)
1. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
[TBL] [Abstract][Full Text] [Related]
3. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
Han G; Yang J; Shao G; Teng G; Wang M; Yang J; Liu Z; Feng G; Yang R; Lu L; Chao Y; Wang J
Future Oncol; 2013 Mar; 9(3):403-10. PubMed ID: 23469975
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Ohki T; Sato K; Yamagami M; Ito D; Yamada T; Kawanishi K; Kojima K; Seki M; Toda N; Tagawa K
Clin Drug Investig; 2015 Nov; 35(11):751-9. PubMed ID: 26446004
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang M; Yuan JQ; Bai M; Han GH
Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
[TBL] [Abstract][Full Text] [Related]
14. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
17. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
[TBL] [Abstract][Full Text] [Related]
18. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
[TBL] [Abstract][Full Text] [Related]
19. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
20. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]